1 Executive Summary
2 AMD and Diabetic Retinopathy
2.1 The Eye
2.1.1 The Human Eye
2.1.2 The Retina and Vision
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 AMD Causes and Risk Factors
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of Diabetic Retinopathy
2.3.2 Non-Proliferative Diabetic Retinopathy
2.3.3 Diabetic Macular Edema
2.3.4 Proliferative Diabetic Retinopathy (PDR)
2.3.5 Risk Factors and Prevalence of Diabetic Retinopathy
2.4 Diagnosis and Prevalence of AMD and DR
2.4.1 Diagnosis
2.4.2 Prevalence
2.5 Other Retinal Disorders
3 Treatments for AMD and Diabetic Retinopathy
3.1 Treatment of Wet AMD
3.1.1 Visudyne
3.1.2 Macugen
3.1.3 Retaane
3.1.4 Lucentis
3.1.5 Avastin
3.2 Treatment of Dry AMD
3.3 Treatments for Diabetic Retinopathy
3.3.1 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
3.3.2 Triamcinolone Acetonide
3.3.3 Lisinopril
3.3.4 VEGF Inhibitors
3.3.5 Dobesilate
4 The World AMD and Diabetic Retinopathy Market, 2009-2024
4.1 The Retinal Disorder Market
4.1.1 The Retinal Disorder Market in 2008
4.1.2 Retinal Disorders Market Forecast, 2009-2014
4.1.3 Retinal Disorders Market Forecast, 2014-2024
4.2 The World AMD Market, 2008
4.2.1 Leading AMD Drugs in 2008
4.2.2 Leading AMD Drug Manufacturers
4.3 AMD Market Forecast
4.3.1 New Treatments for Geographic Atrophy: AMD Market Forecast, 2009-2014
4.3.2 AMD Market Forecast, 2014-2024
4.4 Diabetic Retinopathy Market
4.4.1 The Diabetic Retinopathy Market in 2008
4.4.2 An Alternative to Surgery: Diabetic Retinopathy Market Forecast, 2009-2014
4.4.3 Diabetic Retinopathy Market Forecast, 2014-2024
4.5 Lucentis Sales Forecasts
4.5.1 The Future of Lucentis Hinges on Off-Label Avastin Use
4.5.2 Lucentis Sales Forecast, 2009-2014
4.5.3 Lucentis Sales Forecast, 2014-2024
4.5.4 Alternative Lucentis Sales Forecast, 2009-2024
4.6 Visudyne Sales Forecast, 2009-2014
5 The AMD and Diabetic Retinopathy Pipelines
5.1 The Wet AMD Pipeline
5.1.1 Monoclonal Antibodies and Corticosteroid Implants
5.1.2 siRNA Molecules
5.1.3 Stem Cells and Other Therapies
5.2 The Dry AMD Pipeline
5.3 The Diabetic Retinopathy Pipeline
5.3.1 Corticosteroid Implants
5.3.2 Anti-VEGF Treatments
5.3.3 Early-Stage Diabetic Retinopathy Pipeline
5.4 The Pipeline for Other Retinal Disorders
5.5 AMD and DR Pipeline Drugs in Detail
5.5.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)
5.5.2 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
5.5.3 Bevasiranib (Opko)
5.5.4 Avastin and Lucentis Comparison Trials (CATT)
5.5.5 PF-4523655 (Quark/Pfizer)
5.5.6 Visudyne and Lucentis (QLT/Novartis)
5.5.7 Pazopanib (GSK)
5.5.8 TG100801 (TargeGen)
5.5.9 Zybrestat (Oxigene/Symphony ViDA)
5.5.10 ATG-3 (CoMentis)
5.5.11 Sirolimus (MacuSight/Santen)
5.5.12 Iluvien (Alimera/pSivida)
5.5.13 NT-501 (Neurotech)
5.5.14 OT-551 (Othera)
5.5.15 Sustained-Release Brimonidine (Allergan)
5.5.16 Fenretinide (Sirion Therapeutics)
5.5.17 NT-503 (Neurotech)
5.5.18 Stem Cells (University College of London/Pfizer)
5.5.19 Opko’s siRNA Drug Candidates
5.5.20 Arxxant (Eli Lilly/Alcon/Takeda)
5.5.21 Lucentis (Roche/Novartis)
5.5.22 Macugen (Pfizer)
5.5.23 Vitreosolve (Vitreoretinal Technologies)
5.5.24 Atacand/TCV-116 (AstraZeneca)
5.5.25 Microplasmin (ThromboGenics)
5.5.26 RPE65 Gene Therapy (Targeted Genetics)
5.5.27 QLT091001 (QLT/Retinagenix)
6 Issues Affecting the AMD and Diabetic Retinopathy Pharmaceutical Markets
6.1 SWOT Analysis of the AMD and Diabetic Retinopathy Pharmaceutical Markets
6.2 Intense Research and Development Activity
6.2.1 New Drug Formulations
6.2.2 Sustained-Release Ocular Implants
6.2.3 Novel Biologic Drugs
6.2.4 New Ophthalmic Therapeutic Applications for Drugs
6.3 Off-Label Avastin Use for Retinal Disorders
6.3.1 Avastin and Lucentis
6.3.2 Off-Label Retinal Applications of Avastin
6.3.3 History of Avastin Use for Wet AMD
6.3.4 The CATT Study
6.3.5 The Future for Off-Label Avastin
6.4 ‘Greying’ of the World Population
6.5 Prevalence of Retinal Diseases
6.5.1 Prevalence of AMD, 2008
6.5.2 Forecast AMD Prevalence, 2024
6.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2008
6.5.4 Forecast Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2024
6.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals
6.6.1 Pressure on Healthcare in Current Difficult Economic Environment
6.6.2 Prospects for Reimbursement for AMD and DR Drugs
6.7 Diagnosis and Screening for Retinal Disorders
6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs
6.8.1 Current Laser Treatments
6.8.2 Will Drugs Replace Laser Therapy?
7 AMD and Diabetic Retinopathy Regional Markets
7.1 Retinal Disorder Country Markets, 2008
7.2 Retinal Disorder Regional Forecast, 2009-2024
7.2.1 The US Retinal Disorder Market, 2009-2024
7.2.2 The European Retinal Disorder Market, 2009-2024
7.2.3 The Retinal Disorder Market in the Rest of the World, 2009-2024
8 Opinion from Industry Experts
8.1 Edward Danse, President and CEO of Neurotech
8.1.1 Retinal Disorders with Greatest Unmet Patient Need
8.1.2 Neurotech’s AMD Pipeline
8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients
8.1.4 Screening Programmes for AMD
8.1.5 Potential Lifetime of NT-501 in the Eye
8.1.6 Other Potential Treatments for Geographic Atrophy
8.1.7 Potential Use of NT-501 in Diabetic Retinopathy
8.2 Ken Green, Ph.D., Chief Scientific Officer and Dave Holland, Founder/VP Marketing, Alimera Sciences
8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients
8.2.2 Development of Iluvien for Diabetic Macular Edema
8.2.3 Update on Progress of Iluvien’s Phase III Trials
8.2.4 Reimbursement Prospects for Corticosteroid Inserts
8.2.5 Future for Laser Therapy in Diabetic Retinopathy
8.2.6 Possible Future Treatment for Dry AMD and Geographic Atrophy
8.2.7 Clinical Trials for Iluvien for Wet AMD and RVO
8.3 Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
8.3.1 Othera's Geographic Atrophy Drug: OT-551
8.3.2 New Drugs for Retinal Disorders Currently with No Treatments
9 Conclusions
9.1 AMD and Diabetic Retinopathy
9.2 Increasing Prevalence of AMD and Diabetic Retinopathy
9.3 Current Treatments for AMD and Diabetic Retinopathy
9.4 The Retinal Disorder Market in 2008
9.5 Retinal Disorders Market Forecast, 2009-2024
9.6 Lucentis Market Forecast, 2009-2024
9.7 The AMD and Diabetic Retinopathy Pipelines
9.8 The AMD Pipeline
9.9 The Diabetic Retinopathy Pipeline
List of Tables
Table 2.1 Wet AMD Types
Table 2.2 AMD and DR Diagnosis Methods
Table 2.3 Prevalence of AMD and DR, 2008
Table 2.4 Other Retinal Disorders
Table 3.1 Currently-Marketed AMD Treatments
Table 3.2 Lucentis Regulatory Approval and Launch Dates
Table 4.1 Retinal Disorder Market in 2008
Table 4.2 World Retinal Disorders Market Forecast, 2009-2014
Table 4.3 World Retinal Disorders Market Forecast, 2015-2024
Table 4.4 AMD Market, 2008: Leading Drugs
Table 4.5 AMD Market, 2008: Leading Manufacturers
Table 4.6 Drivers and Restraints for the AMD Market, 2009-2014
Table 4.7 Drivers and Restraints for the DR Market, 2009-2014
Table 4.8 Drivers and Restraints for Lucentis Revenues, 2009-2014
Table 4.9 Lucentis Market Forecast (Main Forecast), 2009-2014
Table 4.10 Lucentis Market Forecast (Main Forecast), 2015-2024
Table 4.11 Lucentis Market Forecast (Alternative Forecast), 2009-2014
Table 4.12 Lucentis Market Forecast (Alternative Forecast), 2015-2024
Table 4.13 Visudyne Market Forecast, 2009-2014
Table 5.1 Key Late-Stage AMD Pipeline Drugs
Table 5.2 Selected Early-Stage AMD Pipeline Drugs
Table 5.3 Key Late-Stage Diabetic Retinopathy Pipeline Drugs
Table 5.4 Selected Early-Stage DR Pipeline Drugs
Table 5.5 Other Retinal Disorder Pipeline Drugs
Table 5.6 Lucentis Clinical Trials in Progress
Table 6.1 SWOT Chart for the AMD and DR Pharmaceutical Markets, 2009
Table 6.2 World Population Forecast, 2008-2024
Table 6.3 Population Forecasts in AMD and DR Markets, 2008 & 2024
Table 6.4 Global, US and European AMD Prevalence, 2008
Table 6.5 Forecast Global, US and European AMD Prevalence, 2024
Table 6.6 Global, US and European DME, PDR and Diabetes Prevalence, 2008
Table 6.7 Forecasted Global, US and European DME, PDR and Diabetes Prevalence, 2024
Table 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
Table 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
Table 7.3 Regional Retinal Disorders Market Forecast, 2015-2024
Table 9.1 Global Prevalence of AMD and DR Complications, 2008 and 2024
List of Figures
Figure 4.1 Retinal Disorder Market in 2008
Figure 4.2 World Retinal Disorder Market Forecast, 2009-2024
Figure 4.3 Revenue Forecast by Retinal Disorder Type, 2009-2024
Figure 4.4 Market Share Forecast by Retinal Disorder Type, 2009-2024
Figure 4.5 AMD Market, 2008: Leading Drugs
Figure 4.6 AMD Market, 2008: Leading Manufacturers
Figure 4.7 Global AMD Market Forecast, 2009-2024
Figure 4.8 Global DR Market Forecast, 2009-2024
Figure 4.9 Lucentis Market Forecast (Main Forecast), 2009-2024
Figure 4.10 Lucentis Market Forecast (Alternative Forecast), 2009-2024
Figure 4.11 Visudyne Market Forecast, 2009-2014
Figure 6.1 Forecasted World Population Aged 65 or Over, 2008-2024
Figure 6.2 Population Forecasts in Leading AMD and DR Markets, 2008 & 2024
Figure 6.3 Global, US and European AMD Prevalence, 2008
Figure 6.4 Global, US and European AMD Prevalence, 2008 and 2024
Figure 6.5 Global, US and European DME and PDR Prevalence, 2008
Figure 6.6 Global, US and European Diabetes Prevalence, 2008 and 2024
Figure 6.7 Global, US and European New Cases of DME, 2008 and 2024
Figure 6.8 Global, US and European New Cases of PDR, 2008 and 2024
Figure 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
Figure 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
Figure 7.3 Market Share Forecast by Regional Retinal Disorder Market, 2009-2024
Figure 9.1 World Retinal Disorder Market Forecast, 2009-2024
Figure 9.2 Lucentis Market Forecast, 2009-2024